GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Acarix AB (OSTO:ACARIX) » Definitions » Research & Development

Acarix AB (OSTO:ACARIX) Research & Development : kr27.35 Mil (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Acarix AB Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Acarix AB's Research & Development for the three months ended in Mar. 2024 was kr4.83 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was kr27.35 Mil.

Acarix AB Research & Development Historical Data

The historical data trend for Acarix AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acarix AB Research & Development Chart

Acarix AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.28 14.47 21.49 27.76 28.52

Acarix AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.07 8.37 6.40 7.76 4.83

Acarix AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr27.35 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acarix AB  (OSTO:ACARIX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Acarix AB Research & Development Related Terms

Thank you for viewing the detailed overview of Acarix AB's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Acarix AB (OSTO:ACARIX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Acarix AB (OSTO:ACARIX) » Definitions » Research & Development
Comparable Companies
OSTO:ARCOMA OSTO:SCIB OSTO:ICO XSAT:PHI XSAT:VSD B NGM:MCLR OSTO:SDOS XSAT:REDS XSAT:CSMED OSTO:NEOLA ABT SYK MDT BSX SZSE:300760 EW DXCM ZBH STE XAMS:PHIA
Traded in Other Exchanges
ACIXF:USA 7AC:Germany
Address
World Trade Center Malmo, Jungmansgatan 12, Malmo, SWE, 211 19
Website
https://www.acarix.com
Acarix AB is a Swedish medical technology company that develops innovative solutions for rapid AI-based exclusion of coronary artery disease (CAD). The CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. The CADScor System uses advanced acoustics and AI technology to non-invasively rule out CAD in less than 10 minutes, with at least 96% certainty.

Acarix AB (OSTO:ACARIX) Headlines

No Headlines